The role of long-term beta-blocker therapy after a myocardial infarction in patients without left ventricular systolic dysfunction or heart failure is unclear in the era of contemporary ...

Aspirin is considered the cornerstone of secondary prevention of coronary artery disease. However, the evidence supporting aspirin was largely generated before the advent of modern pharmacological and ...

A polypill that includes key medications associated with improved outcomes (aspirin, angiotensin-converting–enzyme [ACE] inhibitor, and statin) has been proposed as a simple approach to the secondary ...

The first clinical trial to challenge the routine implantation of a defibrillator in myocardial infarction survivors with heart failure has enrolled its first patient. The PROFID EHRA trial is part of ...

Type 1 diabetes confers a cardiovascular burden that is often obscured by the young age of affected individuals and by the ...

Credit: Getty Images A discussion of the use of beta-blocker therapy following AMI, with Christopher Granger, MD, Gregg Fonarow, MD, and Carlin S Long, MD. Beta blockers have long been included in the ...

Ticagrelor Market Size To Reach USD 3.60 Billion By 2035, Fueled By Rising Cardiovascular Disease Burden And Growing Adoption Of Advanced Antiplatelet Therapies SNS Insider. Increasing Prevalence of ...

In a recent study published in the journal Nature Cardiovascular Research, researchers developed and validated a novel biomarker-based prediction model to evaluate imminent first myocardial infarction ...